Skin Diseases & Skin Care

Comparative evaluation of therapeutic efficacy of intralesional mw vaccine versus intralesional Vitamin D3 versus intralesional tuberculin ppd in cutaneous warts

Cutaneous warts, caused by HPV, are often symptomatic, cosmetically disabling and difficult to treat due to its propensity for recurrence. Intralesional immunotherapy has been found to be efficacious in treatment of cutaneous warts in recent studies.   A total of 90 patients were included in the study. They were randomly divided into 3 groups of 30 patients each. Group 1 patients were given 0.1 ml of Mw vaccine, Group 2 patients were given 0.2 ml to 0.5 ml of intralesional injection of vitamin D3 (60,000 IU, 15mg/ml) and Group 3 patients were given 10 TU/ 0.1 ml of intralesional injection of tuberculin PPD at 3 weeks intervals, until complete clearance of warts or maximum of 4 injections. Follow up was done every 3 weeks for 12 weeks.   At the end of the study, Complete clearance was seen in 27 (90%), 25 (83.33%) and 23 (76.66%) patients; partial response was seen in 3 (10%), 3 (10%) and 4 (13.33%) patients; no response was seen in 0 (0%), 2 (6.66%) and 3 (10%) patients of Group 1 and 2 respectively. There were no serious adverse events or recurrence at 24 weeks follow up in both groups.   Immunotherapy is quite effective and safe in treatment of cutaneous warts. Intralesional Mw and Vitamin D3 shows comparable results in while Intralesional Mw is found more efficacious than Tuberculin PPD.

Author(s):

Amandeep Kaur

Abstract | PDF

Share this